QGEN vs Peers Stock Comparison

Qiagen Prices as of Oct 26, 2026 Peers: Industry group
QGEN Qiagen N.V.
$50.37 +14.0% 1M -3.0% 1Y
Market cap
$10.91B
P/E
26.6x
Revenue (TTM)
$2.10B
Div. yield
–
Life Sciences Tools Healthcare

Percentile Scorecard

QGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisQGEN
Valuation 76 #56 of 228
Growth 30 #155 of 221
Profitability 92 #17 of 208
Financial Health 63 #90 of 239
Shareholder Returns 94 #9 of 137
Overall 71
  • QGEN ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodQGENSPY
1 month +14.0% -0.8%
3 months +22.6% +3.5%
6 months +32.2% +7.0%
Year to date +6.4% +12.2%
1 year -3.0% +13.0%
3 years +25.0% +86.3%
3 years, per year +7.7% +23.1%
5 years -15.6% +68.6%
5 years, per year -3.3% +11.0%
10 years +75.9% +258.0%
10 years, per year +5.8% +13.6%

Risk

MeasureQGENSPY
Volatility, 1Y 35.8% 12.7%
Downside volatility, 1Y 30.5% 12.7%
Beta vs S&P 500, 1Y 0.47 1.00
Return / volatility, 1Y -0.08 1.02
Max drawdown, 5Y -48.2% -25.4%
From 52-week high -9.5% -1.8%
52-week high $55.66 $779.14
52-week low $32.63 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleQGEN
P/E now vs peer median 26.7xmedian 30.6x
P/S now vs peer median 5.2xmedian 3.0x
EV/EBITDA now vs peer median 18.1xmedian 17.5x
P/FCF now vs peer median 11.0xmedian 23.3x
P/B now vs peer median 3.3xmedian 2.4x
PEG now vs peer median 3.62median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsQGEN
Revenue $2.10B
Gross profit $1.31B
Operating income $445.43M
Net income $409.32M
Free cash flow $991.33M
R&D $194.67M
EPS (diluted) $1.87
Cash & equivalents $768.50M
Total debt $6.86B
Shares (diluted) 218.88M
Enterprise value $6.68B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricQGEN
P/E 26.7x
P/FCF 11.0x
P/Operating cash flow 16.7x
P/S 5.2x
P/B 3.3x
P/Tangible book 3.6x
EV/EBITDA 18.1x
EV/EBIT 26.4x
EV/Revenue 5.6x
EV/FCF 11.9x
EV/Operating cash flow 18.0x
PEG (3Y EPS CAGR) 3.62

Growth

14 metrics
MetricQGEN
Revenue growth (1Y) 3.0%
Revenue CAGR (3Y) 2.0%
Gross profit growth (1Y) 1.7%
Gross profit CAGR (3Y) 1.3%
Operating income growth (1Y) -4.9%
Operating income CAGR (3Y) 3.3%
Net income growth (1Y) 143.9%
Net income CAGR (3Y) 6.7%
EPS growth (1Y) 12.5%
EPS CAGR (3Y) 7.4%
Operating cash flow growth (1Y) -3.0%
Operating cash flow CAGR (3Y) 8.0%
Free cash flow growth (1Y) 2.3%
Free cash flow CAGR (3Y) 10.5%

Profitability

14 metrics
MetricQGEN
Gross margin 62.2%
EBITDA margin 31.0%
Operating margin 21.2%
Pretax margin 22.0%
Net margin 19.5%
FCF margin 47.2%
Operating cash flow margin 31.2%
Return on equity 12.2%
Return on assets 7.0%
Return on invested capital 7.9%
Return on capital employed 8.5%
Asset turnover 0.4x
Cash conversion (OCF / net income) 1.6x
Stock comp / revenue 2.1%

Financial Health

11 metrics
MetricQGEN
Debt / assets 27.9%
Debt / equity 0.5x
Net debt / EBITDA 1.3x
Debt / FCF 1.7x
Liabilities / assets 43.0%
Equity / assets 57.0%
Interest coverage 11.3x
Current ratio 2.8x
Quick ratio 2.0x
Cash ratio 1.4x
Altman Z-score 4.08

Shareholder Returns

7 metrics
MetricQGEN
Dividend yield 5.2%
Net buyback yield 0.6%
Shareholder yield 5.8%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusQGEN
Forward P/E 21.4xFY2026
EPS, next fiscal year $2.35FY2026
EPS growth, next FY -1.3%FY2026
EPS growth, the year after +17.4%
Revenue, next fiscal year $2.25BFY2026
Revenue growth, next FY +7.8%FY2026
Revenue growth, the year after -2.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersQGEN
Held by institutions 67.3%
Institutions holding 337
Change in shares held, QoQ +16.5%
Institutions buying 215
Institutions selling 86
Buyers to sellers 2.50

Add a Peer

Largest companies in the same industry

Related Comparisons

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.